SCHEMBL20832811

SCHEMBL20832811

Cn1c(COc2cccc(C(F)(F)F)c2)nnc1-c1ccc(I)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ MAOB P27338 2/20 0.49
▸ MAOA P21397 1/20 0.49
▸ HTR2C P28335 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PPARG P37231 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ GRK2 P25098 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30602686 1.00 L3MBTL1 (0.50) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL20832626 0.89 L3MBTL1 (0.50) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL30602662 0.89 L3MBTL1 (0.50) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL20828450 0.84 L3MBTL1 (0.47) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL20832632 0.83 L3MBTL1 (0.45) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL30602660 0.83 L3MBTL1 (0.45) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL22227863 0.83 PPARG (0.48) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL22623097 0.82 L3MBTL1 (0.57) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL20832818 0.81 L3MBTL1 (0.43) L3MBTL1MAOBMAOAHTR2CLMNA
SCHEMBL30602678 0.81 L3MBTL1 (0.43) L3MBTL1MAOBMAOAHTR2CLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745129-A2 COMPOUND HAVING CYCLIC STRUCTURE Daiichi Sankyo Company, Limited (JP) 2026-05-20 — — EP disclosed
EP-3682881-B1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO CO LTD (JP) 2026-04-01 — — EP disclosed
US-12297187-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-05-13 — — US disclosed
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
CN-111094255-B Compounds having cyclic structures 第一三共株式会社 2023-10-03 — — CN disclosed
US-11512067-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-11-29 — — US disclosed
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
EP-3682881-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-07-22 — — EP disclosed
EP-3682881-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-07-22 — — EP disclosed
CN-111094255-A Compound having cyclic structure 第一三共株式会社 2020-05-01 — — CN disclosed
WO-2019054427-A1 COMPOUND HAVING CYCLIC STRUCTURE 第一三共株式会社 2019-03-21 — — WO disclosed
WO-2019054427-A1 COMPOUND HAVING CYCLIC STRUCTURE 第一三共株式会社 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297187-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885MAOB 575/4885MAOA 1038/4885
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885MAOB 575/4885MAOA 1038/4885
US-11512067-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885MAOB 575/4885MAOA 1038/4885
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885MAOB 575/4885MAOA 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback